WASHINGTON - Biotech drugmaker Cephalon spent more than $512,000 lobbying the federal government in the first quarter, according to a government disclosure form.
| CEPH | 72.62 |
Cephalon lobbied in favor of more funding for the Food and Drug Administration, which reviews the safety of all new medicines in the U.S.
The Frazer, Pa.-based company lobbied Congress on a bill aimed at updating the U.S. patent system. Software and computer companies supported the bill that passed the House last year, saying it would cut down on frivolous patent-infringement lawsuits. But the pharmaceutical industry argued it would weaken patent protections on drugs by reducing infringement penalties. The bill has stalled in the Senate.
Cephalon also lobbied for new standards for alcoholism treatments. The company markets the drug Vivitrol, a monthly injectable treatment for alcoholism.
Along with Congress, Cephalon lobbied the Federal Trade Commission, the White House and the National Institutes of Health.
Cephalon disclosed its lobbying spending in a form filed April 21 with the Senate's office of public records.

Gold experienced a second day of heavy liquidations, following yesterday oil-led and hawkish Fed-induced rout. Significant losses in the euro wer...
China's largest city and the host of a dozen Olympic soccer matches started...
Swedish specialty steelmaker SSAB reported second-quarter pretax profit above market expectations on Thursday and said the global steel market sh...


Professional Website Design For Corporate - Get a Free Quote Today
Find the most up to date research from leading investment firms to make the most informed investing decisions